SALES (Tables)

3 Months Ended

6 Months Ended

Jun. 30, 2012

Jun. 30, 2012

SCHEDULE OF SALES BY PRODUCT TYPE [Table Text Block]

		For the three months ended
		June 30, 2012		June 30, 2011
Human Albumin	$	19,539,419	$	21,377,406
Immunoglobulin products:
Human Hepatitis B Immunoglobulin		2,346,915		1,874,504
Human Immunoglobulin for Intravenous Injection		21,239,174		16,084,281
Human Rabies Immunoglobulin		2,116,013		2,451
Human Tetanus Immunoglobulin		1,879,363		1,951,355
Human Immunoglobulin		645,531		-
Placenta Polypeptide		2,509,202		-
Others		190,722		375,461
Total	$	50,466,339	$	41,665,458

		For the six months ended
		June 30, 2012		June 30, 2011
Human Albumin	$	45,329,702	$	41,078,992
Immunoglobulin products:
Human Hepatitis B Immunoglobulin		3,606,500		4,090,185
Human Immunoglobulin for Intravenous Injection		36,500,900		26,511,668
Human Rabies Immunoglobulin		3,097,572		752,520
Human Tetanus Immunoglobulin		3,313,399		3,140,291
Human Immunoglobulin		755,630		-
Placenta Polypeptide		4,620,011		-
Others		470,086		562,624
Total	$	97,693,800	$	76,136,280